At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 160 enrolled
Drug / intervention
ST-100 Ophthalmic Solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Multi-Center, Randomized, Double Masked, Placebo Controlled Study to Assess the Safety and Efficacy of ST-100 Ophthalmic Solution in Subjects Diagnosed With Dry Eye Disease
In Brief
A Phase 2 clinical trial evaluating ST-100 Ophthalmic Solution and Placebo Ophthalmic Solution for Dry Eye Disease. Completed, enrolled 160 participants across 3 sites.
Detailed Summary
The objective of this study is to compare the safety and efficacy of two different concentrations of ST-100 Ophthalmic Solution to placebo (vehicle) for the treatment of the signs and symptoms of dry eye.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Disease
CountriesUnited States
CollaboratorsORA, Inc.
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartMay 2021
Primary CompletionOct 2021
First PostedFeb 2022
TodayJul 2026
First PostedFeb 15, 2022
Enrollment StartMay 17, 2021
Primary CompletionOct 11, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 4.4 years ago
Interventions
ST-100 Ophthalmic Solutiondrug
One drop in each eye twice a day
Placebo Ophthalmic Solutiondrug
One drop in each eye twice a day